Canadian Biotech Pursues India Partnering Plans For COVID-19 Nasal Spray
Nitric Oxide Shows Promise
Executive Summary
SaNOtize is in partnering talks with large firms in India to manufacture and distribute its nitric oxide nasal spray for COVID-19. The Canadian company believes the product, which already has an interim approval in Israel, could potentially reduce viral load of SARS-CoV-2 variants, as well as influenza and other respiratory viruses.
You may also be interested in...
Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark
Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?
Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.
Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.